Blödarsjuka med HIV. Långsammare infektionsförlopp hos yngre och vid större förbrukning av faktorkoncentrat
(1998) In Läkartidningen 95(1). p.48-50- Abstract
- HIV disease progression and the effect of replacement therapy with clotting factor concentrates (CFCs) were studied in 100 Swedish haemophiliacs, mean age at seroconversion 29 years (range, 4-72). On average 16 years after seroconversion, 67 per cent of the patients had CD4+ cell counts of < 200 x 10(6)/l, 50 per cent had developed AIDS, and 58 per cent had died. HIV disease progression was significantly slower in those aged less than 28 (median age) at seroconversion (P = 0.004). Moreover, mortality was inversely correlated to total annual CFC consumption after adjustment for age and HIV-related therapy, i.e., Pneumocystis carinii prophylaxis and antiretroviral drugs (P = 0.014), but unrelated to the purity of the CFCs used. After... (More)
- HIV disease progression and the effect of replacement therapy with clotting factor concentrates (CFCs) were studied in 100 Swedish haemophiliacs, mean age at seroconversion 29 years (range, 4-72). On average 16 years after seroconversion, 67 per cent of the patients had CD4+ cell counts of < 200 x 10(6)/l, 50 per cent had developed AIDS, and 58 per cent had died. HIV disease progression was significantly slower in those aged less than 28 (median age) at seroconversion (P = 0.004). Moreover, mortality was inversely correlated to total annual CFC consumption after adjustment for age and HIV-related therapy, i.e., Pneumocystis carinii prophylaxis and antiretroviral drugs (P = 0.014), but unrelated to the purity of the CFCs used. After adjustment for age, annual CFC consumption and HIV-therapy, prophylactic replacement therapy was not associated with significantly better survival than on-demand treatment. It is concluded that in HIV-positive haemophiliacs replacement therapy may have a beneficial effect on the immune system, and that CFC purity and the regimen (prophylaxis vs on-demand) would seem to be factors of minor importance. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1113649
- author
- Astermark, Jan LU ; Berntorp, Erik LU ; Stigendal, Lennart and Johnsson, Hans
- organization
- alternative title
- Hemophiliacs with HIV. Slower progression of the infection among younger patients and at higher dosages of factor concentrates
- publishing date
- 1998
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- HIV-positivitet, Blödarsjuka, Hemofili B, Blodburen smitta, Faktor VIII, Faktor IX, Åldersfaktorer, Aids, AIDS-relaterade opportunistiska infektioner
- in
- Läkartidningen
- volume
- 95
- issue
- 1
- pages
- 48 - 50
- publisher
- Swedish Medical Association
- external identifiers
-
- pmid:9458646
- scopus:0032491704
- ISSN
- 0023-7205
- language
- Swedish
- LU publication?
- yes
- additional info
- The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Clinical Coagulation Research Unit (013242510), Emergency medicine/Medicine/Surgery (013240200)
- id
- 3522db93-76f1-47af-af7a-ba3b43b05f2e (old id 1113649)
- alternative location
- http://ltarkiv.lakartidningen.se/artNo16891
- date added to LUP
- 2016-04-01 17:13:45
- date last changed
- 2022-03-23 00:11:25
@article{3522db93-76f1-47af-af7a-ba3b43b05f2e, abstract = {{HIV disease progression and the effect of replacement therapy with clotting factor concentrates (CFCs) were studied in 100 Swedish haemophiliacs, mean age at seroconversion 29 years (range, 4-72). On average 16 years after seroconversion, 67 per cent of the patients had CD4+ cell counts of < 200 x 10(6)/l, 50 per cent had developed AIDS, and 58 per cent had died. HIV disease progression was significantly slower in those aged less than 28 (median age) at seroconversion (P = 0.004). Moreover, mortality was inversely correlated to total annual CFC consumption after adjustment for age and HIV-related therapy, i.e., Pneumocystis carinii prophylaxis and antiretroviral drugs (P = 0.014), but unrelated to the purity of the CFCs used. After adjustment for age, annual CFC consumption and HIV-therapy, prophylactic replacement therapy was not associated with significantly better survival than on-demand treatment. It is concluded that in HIV-positive haemophiliacs replacement therapy may have a beneficial effect on the immune system, and that CFC purity and the regimen (prophylaxis vs on-demand) would seem to be factors of minor importance.}}, author = {{Astermark, Jan and Berntorp, Erik and Stigendal, Lennart and Johnsson, Hans}}, issn = {{0023-7205}}, keywords = {{HIV-positivitet; Blödarsjuka; Hemofili B; Blodburen smitta; Faktor VIII; Faktor IX; Åldersfaktorer; Aids; AIDS-relaterade opportunistiska infektioner}}, language = {{swe}}, number = {{1}}, pages = {{48--50}}, publisher = {{Swedish Medical Association}}, series = {{Läkartidningen}}, title = {{Blödarsjuka med HIV. Långsammare infektionsförlopp hos yngre och vid större förbrukning av faktorkoncentrat}}, url = {{http://ltarkiv.lakartidningen.se/artNo16891}}, volume = {{95}}, year = {{1998}}, }